share_log

Legend Biotech | 6-K: Legend Biotech Announces EU Commission Approval of CARVYKTI for Second-Line Treatment in Patients with Relapsed or Refractory Multiple Myeloma

Legend Biotech | 6-K: Legend Biotech Announces EU Commission Approval of CARVYKTI for Second-Line Treatment in Patients with Relapsed or Refractory Multiple Myeloma

傳奇生物 | 6-K:傳奇生物宣佈CARVYKTI獲歐盟委員會批准用於復發難治性多發性骨髓瘤患者的二線治療
美股sec公告 ·  04/22 13:11
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息